Skip to main content
Journal cover image

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Publication ,  Journal Article
Rini, BI; Battle, D; Figlin, RA; George, DJ; Hammers, H; Hutson, T; Jonasch, E; Joseph, RW; McDermott, DF; Motzer, RJ; Pal, SK; Pantuck, AJ ...
Published in: J Immunother Cancer
December 20, 2019

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

December 20, 2019

Volume

7

Issue

1

Start / End Page

354

Location

England

Related Subject Headings

  • Practice Guidelines as Topic
  • Neoplasm Staging
  • Molecular Targeted Therapy
  • Kidney Neoplasms
  • Immunotherapy
  • Humans
  • Disease Management
  • Carcinoma, Renal Cell
  • Biomarkers, Tumor
  • Antineoplastic Agents, Immunological
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rini, B. I., Battle, D., Figlin, R. A., George, D. J., Hammers, H., Hutson, T., … Atkins, M. B. (2019). The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer, 7(1), 354. https://doi.org/10.1186/s40425-019-0813-8
Rini, Brian I., Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, et al. “The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).J Immunother Cancer 7, no. 1 (December 20, 2019): 354. https://doi.org/10.1186/s40425-019-0813-8.
Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354.
Rini, Brian I., et al. “The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).J Immunother Cancer, vol. 7, no. 1, Dec. 2019, p. 354. Pubmed, doi:10.1186/s40425-019-0813-8.
Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354.
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

December 20, 2019

Volume

7

Issue

1

Start / End Page

354

Location

England

Related Subject Headings

  • Practice Guidelines as Topic
  • Neoplasm Staging
  • Molecular Targeted Therapy
  • Kidney Neoplasms
  • Immunotherapy
  • Humans
  • Disease Management
  • Carcinoma, Renal Cell
  • Biomarkers, Tumor
  • Antineoplastic Agents, Immunological